NCT00805961 2021-12-08
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
Phase 2 Completed
SCRI Development Innovations, LLC
Servier
Aalborg University Hospital
National Cancer Institute, Egypt
Fenway Community Health
SCRI Development Innovations, LLC
European Organisation for Research and Treatment of Cancer - EORTC
Uppsala University
University of Rhode Island
Mayo Clinic